New approaches for the management of cervical cancer

Gynecologic Oncology

Volumn 90, Issue 3 SUPPL., 2003, Pages

  Herzog, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; Chemotherapy; Human papillomavirus; Radiotherapy; Surgery

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; HUMAN PAPILLOMA 16 L1 VIRUS LIKE PARTICLE VACCINE; HYDROXYUREA; METHOTREXATE; PLACEBO; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VIRUS VACCINE;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE FERTILITY; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; INJECTION SITE; LAPAROSCOPIC SURGERY; LAPAROSCOPY; LAPAROTOMY; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PAPANICOLAOU TEST; PELVIS LYMPHADENECTOMY; POSITRON EMISSION TOMOGRAPHY; PRECANCER; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; SCAR FORMATION; SURGICAL TECHNIQUE; TREATMENT INDICATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL HYSTERECTOMY; VIRUS ETIOLOGY; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

EID: 0041731929     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00466-9     Document Type: Conference Paper

References (30)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2:2001;533-543.
2. WHO statistics. http://www3.who.int/whosis/menu.cfm [Accessed 12 August 2003].
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al., editors. SEER cancer statistics review, 1975-2000, Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2000, 2003. [Accessed 13 June 2003].
4. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relationship between human papillomavirus and cervical cancer. J Clin Pathol. 55:2002;241-242.
5. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;1-3.
6. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalance of human papillomavirus in cervical cancer a worldwide perspective . J Natl Cancer Inst. 87:1995;796-802.
7. Fiorica J.V. Update on the treatment of cervical and uterine carcinoma focus on topotecan . Oncologist. 7:(suppl 5):2002;36-45.
8. Creasman W.T. New gynecologic cancer staging. Gynecol Oncol. 58:1995;157-158.
9. Cannistra S.A., Niloff J.M. Cancer of the uterine cervix. N Engl J Med. 334:1996;436-442.
10. Fiorica JV, The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol 2003;90(3):S16-21.
11. Dargent D. Radical trachelectomy an operation that preserves the fertility of young women with invasive cervical cancer . Bull Acad Natl Med. 185:2001;1295-1304.
12. Rodriguez M., Guimares O., Rose P.G. Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer. Am J Obstet Gynecol. 185:2001;370-374.
13. Roy M., Plante M., Renaud M.-C., Tetu B. Vaginal hysterectomy versus abdominal radical hysterectomy in the treatment of early-stage cervical cancer. Gynecol Oncol. 62:1996;336-339.
14. Spirtos N.M., Schlaerth J.B., Kimball R.E., Leiphart V.M., Ballon S.C. Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenopathy. Am J Obstet Gynecol. 74:1996;1763-1767.
15. Schlaerth J.B., Spirtos N.M., Carson L.F., Boike G., Adamec T., Stonebraker B. Laparoscopic retroperitoneal lymphadenectomy followed by immediate laparotomy in women with cervical cancer a Gynecologic Oncology Group study . Gynecol Oncol. 85:2002;81-88.
16. Inoue T. Prognostic significance of the depth of invasion relating to nodal metastases, parametrial extension, and cell types. A study of 628 cases with stage IB, IIA, and IIB cervical carcinoma. Cancer. 54:1984;3035-3042.
17. Miller T.R., Grigsby P.W. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 53:2002;353-359.
18. Rose P.G., Adler L.P., Rodriguez M., Faulhaber P.F., Abdul-Karim F.W., Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging a surgicopathologic study . J Clin Oncol. 17:1999;41-45.
19. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1999;1144-1153.
20. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1999;1198-1200.
21. Morris M., Eifel P., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1999;1137-1143.
22. Peters W.A., Liu P.Y., Barrett R.J. III, Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 18:2000;1606-1613.
23. Whitney C.W., Sause W., Bundy B.M., Malfetano J.H., Hannigan E.V., Fowler W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes a Gynecologic Oncology Group and Southwest Oncology Group Study . J Clin Oncol. 17:1999;1339-1348.
24. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus 16-transformed cells. Eur J Immunol. 23:1993;2242-2249.
25. Donnelly J.J., Martinez D., Jansen K.U., Ellis R.W., Montgomery D.L., Liu M.A. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis. 173:1996;314-320.
26. Rose R.C., Iane C., Wilson S., Suzich J.A., Rybicki E., Williamson A.L. Oral vaccination of mice with human papillomavirus-like particles induces systemic virus-neutralizing antibodies. Vaccine. 17:1999;2129-2135.
27. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine. 18:2000;1051-1058.
28. Borysiewicz L.K., Flanders A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
29. Blachere N.E., Li Z., Chandawarker R.Y., Suto R., Jaikaria N.S., Basu S., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med. 186:1997;1315-1322.
30. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 347:2002;1645-1651.